Developing novel medicines through next generation targeted protein degradation.

Amphista Therapeutics is developing medicines for hard to treat diseases using next generation targeted protein degradation approaches. Our portfolio uses our own novel protein degrading mechanisms which build on the strengths of current protein degradation approaches whilst directly addressing their limitations.

or why not drop us an email

About us

Amphista Therapeutics is an exciting spin out company founded by Advent Life Sciences and built on groundbreaking science from the laboratory of Professor Alessio Ciulli (University of Dundee), a world leader in the field of targeted protein degradation.

Targeted Protein Degradation

Targeted protein degradation (TPD) hijacks the cell’s degradation machinery to modulate abundance of proteins that are responsible for disease progression. Our approach to protein degradation differentiates from traditional TPD technologies and is being developed to treat diseases with high unmet need.

Find Out More


Amphista is searching for innovative, and highly motivated individuals who enjoy teamwork and are comfortable working in a fast-paced entrepreneurial environment.

Find Out More

Drop us a line

We are here to answer any question you may have

Contact Us

Left Half

By submitting this form you agree to our Terms & Conditions and Privacy Policy.

Right Half

Our Address

BioCity, Bo’Ness Rd, Newhouse, Chapelhall, Motherwell, ML1 5UH, UK

Registered Address

158-160 North Gower Street, London, England, NW1 2ND, UK